NOVEMBER 2024LIFE SCIENCES REVIEW6The European therapeutics landscape is experiencing transformative shifts, driven by breakthroughs in AI-driven drug discovery, personalised medicine and CRISPR-based gene editing. AI algorithms are streamlining early-stage drug discovery by analysing massive datasets to predict therapeutic targets and optimise molecule designs with exceptional precision. This approach aims to accelerate the development timeline, reducing both time and costs significantly. Alongside AI, CRISPR advancements, such as CRISPR-Cas9 and base-editing techniques, are showing promising potential to address genetic disorders previously deemed untreatable. These innovations are supported by progressive European regulatory frameworks that prioritise patient-centred and efficient therapeutic solutions.Cell and gene therapies are also evolving, with European research institutions and biopharmaceutical companies increasingly focusing on scalable production techniques and cross-border collaboration. Next-generation CAR-T therapies and RNA-based treatments for rare diseases are paving the way for highly personalised treatments tailored to individual patient genetics and specific disease profiles. Additionally, Europe is investing in biomanufacturing facilities to support rapid production capabilities while meeting emerging green standards.Driven by these trends, the global targeted therapeutics market is expected to grow at a CAGR of 6.83 percent during the forecast period of 2024 to 2034.In this edition of Life Sciences Review Europe, we provide insights into recent developments in the therapeutics market and how companies offer services aligned with the latest trends.The magazine features a thought leadership article from Nelly Marmy Conus, Patient and Site Clinical Trial Digital Solutions Lead at Syneos Health, who highlights the importance of long-term follow-up for cell and gene therapy trials and introduces a centralised megasite approach to overcome the difficulties of traditional methods. It also features an article by Anne Marie Morse, Director, Division of Paediatric Sleep Medicine, Geisinger, who sheds light on the critical role of sleep in overall health and well-being, highlighting its importance as a modifiable biomarker for risk stratification and management across various clinical scenarios.In this edition featuring the Top Therapeutics Companies in Europe 2024, we hope you find the right partner to meet your organisation's needs.Let us know your thoughts!EDITORIALThe Rise of Targeted TherapeuticsCopyright © 2024 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com NOVEMBER - 11 - 2024, Vol 05, Issue - 43 (ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasVisualizerRonald DonovanDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsHenry SmithClara Matthew
< Page 5 | Page 7 >